Loading…
Loading…
VRCI does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VRCI and 80,000+ other tickers.
See exactly how VRCI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VRCI and 80,000+ other tickers.
Verde Science, Inc., a pharmaceutical research and development enterprise, is dedicated to advancing a diverse array of prescription medications derived from cannabinoids, intended for the treatment of numerous health conditions. The company, which initially operated as Rango Energy, Inc., officially transitioned to the name Verde Science, Inc. in May 2014. Established in 2007, the company maintains its operational headquarters in Dallas, Texas.
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher's Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Company also received NY state approval of Tutivia™, its blood-based laboratory developed test (LDT) that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score c.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assa.
Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American Pathologists (CAP), one of the leading US bodies for clinical laboratory accreditation. The inspection passed with no deficiencies, confirming the company's continued compliance with CAP's rigorous quality and operational standards.
Verici Dx PLC (AIM:VRCI) shares skipped 12% higher to 0.7p after the developer of diagnostic tests for organ transplants bagged a new agreement with a healthcare network in the United States. The deal with Prime Health Services sees Verici Dx join a preferred provider network, giving its services access to more than 850,000 healthcare providers and 35 million insurance claims a year.